Dyne Therapeutics Target of Unusually Large Options Trading (NASDAQ:DYN)

Posted by on Sep 8th, 2026

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Stock traders purchased 20,532 call options on the stock. This represents an increase of approximately 4,325% compared to the average volume of 464 call options.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on DYN shares. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Monday, August 17th. Morgan Stanley reduced their price objective on Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Royal Bank Of Canada upped their price objective on Dyne Therapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, July 30th. Cantor Fitzgerald began coverage on Dyne Therapeutics in a research report on Thursday, July 23rd. They set an “overweight” rating for the company. Finally, Evercore set a $33.00 target price on shares of Dyne Therapeutics in a report on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $34.42.

Check Out Our Latest Analysis on DYN

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Jason Rhodes sold 2,160,516 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the transaction, the director owned 428,946 shares in the company, valued at approximately $10,723,650. This represents a 83.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Erick Lucera sold 2,362 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total transaction of $48,113.94. Following the transaction, the chief financial officer directly owned 121,563 shares of the company’s stock, valued at $2,476,238.31. The trade was a 1.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 4,139,196 shares of company stock worth $99,449,852 in the last three months. Insiders own 9.46% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Handelsbanken Fonder AB bought a new stake in shares of Dyne Therapeutics during the 2nd quarter worth approximately $1,182,000. Fisher Asset Management LLC bought a new position in Dyne Therapeutics in the 4th quarter valued at $4,891,000. Royal Bank of Canada grew its position in Dyne Therapeutics by 267.6% in the 1st quarter. Royal Bank of Canada now owns 68,188 shares of the company’s stock valued at $1,236,000 after acquiring an additional 49,641 shares during the last quarter. Cibc World Market Inc. purchased a new stake in Dyne Therapeutics in the fourth quarter worth $1,345,000. Finally, Clearbridge Investments LLC bought a new stake in shares of Dyne Therapeutics during the fourth quarter worth $7,976,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Trading Down 15.3%

Shares of NASDAQ DYN traded down $3.72 during trading hours on Tuesday, hitting $20.56. 8,258,039 shares of the company traded hands, compared to its average volume of 2,094,361. The stock has a market capitalization of $3.84 billion, a price-to-earnings ratio of -6.23 and a beta of 1.08. The company’s 50 day moving average price is $24.86 and its 200 day moving average price is $20.45. Dyne Therapeutics has a 12 month low of $11.92 and a 12 month high of $27.31. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, equities research analysts anticipate that Dyne Therapeutics will post -3.47 earnings per share for the current fiscal year.

Dyne Therapeutics Company Profile

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

Featured Stories

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.